Mesenchymal stem cells for the treatment of systemic lupus erythematosus: Is the cure for connective tissue diseases within connective tissue?

Flavio A. Carrion, Fernando E. Figueroa

Research output: Contribution to journalScientific reviewpeer-review

27 Scopus citations

Abstract

Mesenchymal stem cells (MSCs) are now known to display not only adult stem cell multipotency but also robust anti-inflammatory and regenerative properties. After widespread in vitro and in vivo preclinical testing in several autoimmune disease models, allogenic MSCs have been successfully applied in patients with severe treatment-refractory systemic lupus erythematosus. The impressive results of these uncontrolled phase I and II trials - mostly in patients with non-responding renal disease - point to the need to perform controlled multicentric trials. In addition, they suggest that there is much to be learned from the basic and clinical science of MSCs in order to reap the full potential of these multifaceted progenitor cells in the treatment of autoimmune diseases.
Original languageAmerican English
JournalStem Cell Research and Therapy
Volume2
Issue number3
DOIs
StatePublished - 9 Sep 2011

Fingerprint Dive into the research topics of 'Mesenchymal stem cells for the treatment of systemic lupus erythematosus: Is the cure for connective tissue diseases within connective tissue?'. Together they form a unique fingerprint.

Cite this